51 research outputs found
Hemoglobin E syndromes in Pakistani population
<p>Abstract</p> <p>Background</p> <p>Hemoglobin E is an important hemoglobin variant with a worldwide distribution. A number of hemoglobinopathies have been reported from Pakistan. However a comprehensive description of hemoglobin E syndromes for the country was never made. This study aimed to describe various hemoglobin E disorders based on hematological parameters and chromatography. The sub-aim was to characterize hemoglobin E at molecular level.</p> <p>Methods</p> <p>This was a hospital based study conducted prospectively for a period of one year extending from January 1 to December 31, 2008. EDTA blood samples were analyzed for completed blood counts and hemoglobin variants through automated hematology analyzer and Bio-Rad beta thalassaemia short program respectively. Six samples were randomly selected to characterize HbE at molecular level through RFLP-PCR utilizing <it>Mnl</it>I restriction enzyme.</p> <p>Results</p> <p>During the study period, 11403 chromatograms were analyzed and Hb E was detected in 41 (or 0.36%) samples. Different hemoglobin E syndromes identified were HbEA (n = 20 or 49%), HbE/β-thalassemia (n = 14 or 34%), HbEE (n = 6 or 15%) and HbE/HbS (n = 1 or 2%). Compound heterozygosity for HbE and beta thalassaemia was found to be the most severely affected phenotype. RFLP-PCR utilizing <it>Mnl</it>I successfully characterized HbE at molecular level in six randomly selected samples.</p> <p>Conclusions</p> <p>Various HbE phenotypes are prevalent in Pakistan with HbEA and HbE/β thalassaemia representing the most common syndromes. Chromatography cannot only successfully identify hemoglobin E but also assist in further characterization into its phenotype including compound heterozygosity. Definitive diagnosis of HbE can easily be achieved through RFLP-PCR.</p
Measurement of Λb0 , Λc+ , and Λ decay parameters using Λb0→Λc+h− decays
A comprehensive study of the angular distributions in the bottom-baryon decays
Λ0
b → Λ
c+h−(h = π, K), followed by Λþ
c → Λhþ with Λ → pπ− or Λþ
c → pK0
S decays, is performed
using a data sample of proton-proton collisions corresponding to an integrated luminosity of 9 fb−1
collected by the LHCb experiment at center-of-mass energies of 7, 8, and 13 TeV. The decay parameters
and the associated charge-parity (CP) asymmetries are measured, with no significant CP violation
observed. For the first time, the Λ0
b → Λþ
c h− decay parameters are measured. The most precise
measurements of the decay parameters α, β, and γ are obtained for Λþ
c decays and an independent
measurement of the decay parameters for the strange-baryon Λ decay is provided. The results deepen our
understanding of weak decay dynamics in baryon decays
Airway obstruction due to a laryngeal polyp following insertion of a laryngeal mask airway
Distinctive inhibition of alkaline phosphatase isozymes by thiazol‐2‐ylidene‐benzamide derivatives: Functional insights into their anticancer role
Selective Aerobic Oxidation of 5-Hydroxymethylfurfural in Water Over Solid Ruthenium Hydroxide Catalysts with Magnesium-Based Supports
Solid catalyst systems comprised of ruthenium hydroxide supported on magnesium-based carrier materials (spinel, magnesium oxide and hydrotalcite) were investigated for the selective, aqueous aerobic oxidation of the biomass-derived chemical 5-hydroxymethylfurfural into 2,5-furandicarboxylic acid (FDA), a possible plastics precursor. The novel catalyst systems were characterized by nitrogen physisorption, XRPD, TEM and EDS analysis, and applied for the oxidation with no added base at moderate to high pressures of dioxygen and elevated temperatures. The effects of support, temperature and oxidant pressure were studied and optimized to allow a quantitative yield of FDA to be obtained
Validation of self-reported adherence in chronic patients visiting pharmacies and factors associated with the overestimation and underestimation of good adherence
pH/NIR Light-Controlled Multidrug Release via a Mussel-Inspired Nanocomposite Hydrogel for Chemo-Photothermal Cancer Therapy
- …
